Indian drug company Dr Reddy's plans to use its net cash surplus of INR 5,000 crore ($670m) to fund acquisitions and innovations aiming at India, the US and emerging markets. CEO Erez Israeli said the funds would be used for product-acquiring licences, and added that the company
